全文获取类型
收费全文 | 1315篇 |
免费 | 65篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 73篇 |
妇产科学 | 31篇 |
基础医学 | 138篇 |
口腔科学 | 84篇 |
临床医学 | 101篇 |
内科学 | 305篇 |
皮肤病学 | 20篇 |
神经病学 | 22篇 |
特种医学 | 259篇 |
外科学 | 97篇 |
综合类 | 17篇 |
预防医学 | 88篇 |
眼科学 | 22篇 |
药学 | 60篇 |
1篇 | |
中国医学 | 11篇 |
肿瘤学 | 52篇 |
出版年
2022年 | 6篇 |
2021年 | 23篇 |
2020年 | 11篇 |
2019年 | 20篇 |
2018年 | 16篇 |
2017年 | 17篇 |
2016年 | 18篇 |
2015年 | 33篇 |
2014年 | 37篇 |
2013年 | 39篇 |
2012年 | 61篇 |
2011年 | 63篇 |
2010年 | 45篇 |
2009年 | 45篇 |
2008年 | 43篇 |
2007年 | 37篇 |
2006年 | 47篇 |
2005年 | 31篇 |
2004年 | 20篇 |
2003年 | 20篇 |
2002年 | 32篇 |
2001年 | 26篇 |
2000年 | 18篇 |
1999年 | 22篇 |
1998年 | 44篇 |
1997年 | 35篇 |
1996年 | 39篇 |
1995年 | 48篇 |
1994年 | 41篇 |
1993年 | 43篇 |
1992年 | 16篇 |
1991年 | 9篇 |
1990年 | 13篇 |
1989年 | 44篇 |
1988年 | 27篇 |
1987年 | 32篇 |
1986年 | 41篇 |
1985年 | 21篇 |
1984年 | 20篇 |
1983年 | 15篇 |
1982年 | 18篇 |
1981年 | 19篇 |
1980年 | 19篇 |
1979年 | 10篇 |
1978年 | 15篇 |
1977年 | 16篇 |
1976年 | 15篇 |
1975年 | 14篇 |
1973年 | 6篇 |
1957年 | 6篇 |
排序方式: 共有1384条查询结果,搜索用时 265 毫秒
1.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
2.
Paulo Cezar Galv?o do Amaral Euler de Medeiros ázaro Filho Thales Delmondes Galv?o Ettinger Eric Junior Galeno Egydio José de Magalh?es Neto Fabrício Mascarenhas Edvaldo Fahel 《JSLS, Journal of the Society of Laparoendoscopic Surgeons》2006,10(3):355-358
BACKGROUND: Randomized studies demonstrate that laparoscopic appendectomy yields better results compared with open techniques. We sought to identify factors that determine an extended hospital stay among patients undergoing laparoscopic appendectomy. METHODS: This was a prospective study including 669 patients undergoing laparoscopic appendectomy. We analyzed variables that can predict the length of hospital stay. RESULTS: Of 669 patients undergoing laparoscopic appendectomy, 141 stayed in the hospital for > or = 5 days (Group 1), and 97 stayed in the hospital for < or = 1 day after surgery (Group 2). The univariate analysis demonstrated that fever (P<0.0001), nausea and vomiting (P=0.060), leukocytosis (P<0.0001), gangrened or perforated intraoperative appearance of the appendix (P<0.0001), and appendix position behind the ileocecal junction (P<0.001) were related to a longer hospital stay. The multivariate analysis through logistical regression showed that the factors independently and significantly associated with an extended hospital stay were presurgical fever, appendix position behind the ileocecal junction, and intraoperative gangrened or perforated appearance of the appendix. CONCLUSION: Fever, appearance, and position of the appendix are factors related to an extended hospital stay. 相似文献
3.
4.
RAFAEL BEYAR M.D. D.Sc. ARIEL ROGUIN M.D. JAAP HAMBURGER M.D. RE SAAIMAN M.D. ANTONIO L. BARTORELLI M.D. CARLO DiMARIO M.D. ANTONIO COLOMBO M.D. CHRISTIAN W. HAMM M.D. CHRISTOPHER J. WHITE M.D. J. MARCO M.D. PATRICK W. SERRUYS M.D. Ph.D. 《Journal of interventional cardiology》1997,10(4):277-286
The beStent is a new stainless steel, balloon-expandable mesh stent which has a unique serpentine design. Rotation of the unique low stress junctions upon expansion leads to orthogonal locking of the wires, maximizing radial strength and assuring zero shortening. The stent has delineating gold markers which assure precise positioning. We aim to present the initial acute results in a pilot registry for stent evaluation. Two hundred eighty-four stents were used in a total of 217 patients (age 57.9 ± 3.10 years; 178 males; 39 females) in seven centers, for variable indications. Stents of 15-, 25-, and 35-mm length were used. The arteries treated were the left anterior descending (n = 112, 42%), circumflex (n = 54, 20.2%), right coronary (n = 95, 35.5%), left main (n = 1, 0.4%), and vein graft (n = 5, 1.9%). Lesion types were: A in 42 patients (16.5%); B1 in 53 patients (20.7%); B2 in 81 patients (31.8%); and C in 79 patients (31%). One hundred fifty-nine patients required one stent, 40 patients required two stents, and 18 patients required three or more stents. Anticoagulation protocol included procedural heparin with aspirin with/without ticlopidine. Smooth angiographie results were obtained in all cases with no plaque herniation. Acute angiographic success was obtained in 97% of the patients, and acute clinical success in 95% of the patients. Complications within 30 days were: 3 deaths (1.4%) (2 noncardiac); 2 (0.9%) myocardial infarctions; and 2 (0.9%) stent thromboses. Therefore, the beStent is useful in treatment of complex lesions of variable length and complexity, providing excellent acute results with a low complication rate, in spite of unfavorable basic clinical and angiographie characteristics. 相似文献
5.
6.
Perfluorochemicals as US contrast agents for tumor imaging and hepatosplenography: preliminary clinical results 总被引:3,自引:0,他引:3
Mattrey RF; Strich G; Shelton RE; Gosink BB; Leopold GR; Lee T; Forsythe J 《Radiology》1987,163(2):339-343
In animals, perfluorochemicals (PFCs) are effective ultrasound (US) contrast agents that produce hepatic, splenic, and tumor enhancement. The use of Fluosol-DA 20%, an emulsion of perfluorodecalin and perfluorotripropylamine, was studied in nine non-critically ill patients with cancer who had liver lesions. US studies without Fluosol were compared with studies obtained 24, 48, and 72 hours after Fluosol infusion. Vital signs and extensive laboratory analyses are performed before and after Fluosol infusion. Liver metastases from colonic, pancreatic, and gastric carcinoma exhibited rim or diffuse enhancement after a Fluosol dose of 1.6 g/kg or greater. Fluosol produced echogenic enhancement of the liver and spleen relative to kidney at a dose of 2.4 g/kg, allowing the detection of nonenhancing lesions. In addition, Fluosol at a dose of 1.6 g/kg or greater allowed detection of lesions not seen before contrast medium was administered in three of the seven patients studied. There was a mild increase in the level of serum glutamic oxaloacetic transaminase in two patients, one given 2.4 and the other 3.2 g/kg of Fluosol. Mild and transient allergic reactions without change in vital signs were experienced by two patients. 相似文献
7.
8.
9.
Coralline hydroxyapatite bone graft substitutes: preliminary report of radiographic evaluation 总被引:1,自引:0,他引:1
A new bone graft substitute made by conversion of the calcium carbonate exoskeleton of reef-building sea coral into hydroxyapatite has recently become clinically available. The normal radiographic appearance of two forms of this material is described. In the immediate postoperative period, the exoskeletal architecture of these implants is readily appreciated. With graft incorporation over the ensuing months, their intrinsic structure is gradually lost in association with poor marginal definition. Evolving radiographic findings reflect the biocompatible nature of these implants, which provides the potential for ingrowth of native bone with preservation of the coralline scaffold, resulting in enhanced biomechanical properties. 相似文献
10.
Mascarenhas Leo; Stripecke Renata; Case Scott S.; Xu Dakun; Weinberg Kenneth I.; Kohn Donald B. 《Blood》1998,92(10):3537-3545
Autologous leukemia cells engineered to express immune-stimulatingmolecules may be used to elicit antileukemia immune responses. Genedelivery to human B-precursor acute lymphoblastic leukemia (ALL) cellswas investigated using the enhanced green fluorescent protein (EGFP) asa reporter gene, measured by flow cytometry. Transfection of the Nalm-6and Reh B-precursor ALL leukemia cell lines with an expression plasmidwas investigated using lipofection, electroporation, and a polycationiccompound. Only the liposomal compound Cellfectin showed significantgene transfer (3.9% to 12% for Nalm-6 cells and 3.1% to 5% for Rehcells). Transduction with gibbon-ape leukemia virus pseudotyped Moloneymurine leukemia virus (MoMuLV)-based retrovirus vectors wasinvestigated in various settings. Cocultivation of ALL cell lines withpackaging cell lines showed the highest transduction efficiency forretroviral gene transfer (40.1% to 87.5% for Nalm-6 cells and 0.3%to 9% for Reh cells), followed by transduction with viral supernatant on the recombinant fibronectin fragment CH-296 (13% to 35.5% for Nalm-6 cells and 0.4% to 6% Reh cells), transduction on human bonemarrow stroma monolayers (3.2% to 13.3% for Nalm-6 cells and 0% to0.2% Reh cells), and in suspension with protamine sulfate (0.7% to3.1% for Nalm-6 cells and 0% for Reh cells). Transduction of bothNalm-6 and Reh cells with human immunodeficiency virus-type 1 (HIV-1)-based lentiviral vectors pseudotyped with the vesicular stomatitis virus-G envelope produced the best gene transfer efficiency, transducing greater than 90% of both cell lines. Gene delivery intoprimary human B-precursor ALL cells from patients was then investigatedusing MoMuLV-based retrovirus vectors and HIV-1-based lentivirusvectors. Both vectors transduced the primary B-precursor ALL cells withhigh efficiencies. These studies may be applied for investigating genedelivery into primary human B-precursor ALL cells to be used forimmunotherapy. 相似文献